Anti Cancer CAS 871700-17-3 Raw Material Trametinib API Trametinib

Still deciding? Get samples of $ !
Request Sample

Product Description

Basic Information
Model NO.:QS-Trametinib
Certification:GMP, HSE, ISO 9001, USP, BP
Suitable for:Elderly, Children, Adult
State:Powder
Purity:>99%
CAS:871700-17-3
MF:C26H23FIN5O4
Appearance:White Powder
Capacity:1000kg/Month
Product Description
Trametinib is an oral MEK (mitogen-activated protein kinase kinase) inhibitor-targeted antineoplastic drug. Its core mechanism of action is to specifically inhibit the activity of MEK1/2 proteins, blocking the abnormal activation of the RAS-RAF-MEK-ERK signaling pathway. This pathway is often mutated and activated in various tumor cells, leading to uncontrolled proliferation and survival of tumor cells.
Product Details
Product NameTrametinib
AppearanceWhite Powder
CAS No.871700-17-3
Molecular FormulaC26H23FIN5O4
Molecular Weight615.402623
Application & Function
Trametinib is a selective, oral mitogen-activated protein kinase (MEK) inhibitor, a type of targeted antineoplastic agent primarily used for the treatment of advanced or metastatic cancers harboring activating mutations in the BRAF gene. It specifically binds to and inhibits MEK1/2, blocking the abnormal activation of ERK and interrupting the signaling cascade that promotes tumor cell proliferation.
Specification & COA
Certificate of Analysis
Frequently Asked Questions
Q1: What is the purity of your Trametinib powder? A: Our Trametinib API maintains a high purity level of over 99%, as confirmed by HPLC testing.
Q2: What certifications does the product have? A: The product is manufactured under GMP, HSE, and ISO 9001 standards, complying with USP and BP specifications.
Q3: What is the primary application of Trametinib? A: It is primarily used as a targeted pharmaceutical agent for advanced or metastatic cancers involving BRAF mutations.
Q4: How is the product transported? A: We offer flexible and negotiable transport packages to ensure the stability and safety of the powder during transit.
Q5: What is your monthly production capacity? A: Our current production capacity for Trametinib is approximately 1000kg per month.
Q6: Can I request a Certificate of Analysis (COA)? A: Yes, every batch is accompanied by a detailed COA and test results from HPLC analysis.

Related Products